0
0

Encouraging Innovative Benefit Design to Lower Costs for Seniors Act

10/28/2022, 1:46 AM

Congressional Summary of S 3013

Encouraging Innovative Benefit Design to Lower Costs for Seniors Act

This bill allows prescription drug plan (PDP) sponsors under the Medicare prescription drug benefit to offer additional plans in a region.

Specifically, the Centers for Medicare & Medicaid Services (CMS) must update guidance to allow PDP sponsors to offer up to four plans in a region; the CMS may also set a greater limit, as appropriate.

PDP sponsors may offer up to two additional plans beyond this limit if the PDP sponsor ensures that, under at least one of the plans, pharmacy benefit managers do not receive any remuneration unless at least 10% of price reductions received from drug manufacturers are reflected at the point-of-sale or otherwise used to reduce beneficiary cost-sharing.

Current Status of Bill S 3013

Bill S 3013 is currently in the status of Bill Introduced since December 10, 2019. Bill S 3013 was introduced during Congress 116 and was introduced to the Senate on December 10, 2019.  Bill S 3013's most recent activity was Read twice and referred to the Committee on Finance. as of December 10, 2019

Bipartisan Support of Bill S 3013

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
2
Democrat Cosponsors
0
Republican Cosponsors
2
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 3013

Primary Policy Focus

Health

Potential Impact Areas

- Government information and archives
- Health care costs and insurance
- Health care coverage and access
- Insurance industry and regulation
- Medicare
- Prescription drugs

Alternate Title(s) of Bill S 3013

Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
Encouraging Innovative Benefit Design to Lower Costs for Seniors Act
A bill to amend title XVIII of the Social Security Act to allow for the offering of additional prescription drug plans under Medicare part D.

Comments